THE EMERGENT SCIENCE OF HDL AND ITS METABOLISM: Mechanistic Understanding of CETP Antagonism and Beyond

The Emergent Science of HDL and its Metabolism
1 ACPE 1 ANCC Contract Hours 1 CDR 1 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Peter P. Toth, MD, PhD, FNLA*

Peter P. Toth, MD, PhD, FNLA*
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
Chief of Medicine, CGH Medical Center
Sterling, Illinois
Clinical Professor
University of Illinois School of Medicine
Peoria, IL

Peter P. Toth, MD, PhD received his bachelor's degree in biochemistry from Princeton University and a PhD in biochemistry from Michigan State University. He graduated from Wayne State University School of Medicine and completed residency training in family medicine at the University of Iowa Hospitals and Clinics.
Dr. Toth is a Diplomate of the American Board of Family Practice and the American Board of Clinical Lipidology. He is a member of the American College of Cardiology Foundation Council on Cardiovascular Disease Prevention and the American Heart Association's Council on Lipoproteins, Lipid Metabolism, and Thrombosis.
Dr. Toth has authored or co-authored more than 220 publications in medical and scientific journals and textbooks. He is Editor-in-Chief of the Year in Lipid Disorders (Atlas Publishing, Oxford, UK) and an Associate Editor for the Year Book of Endocrinology. He is co-editor with Antonio Gotto on the textbook, Comprehensive Management of High Risk Cardiovascular Patients (Taylor and Francis, New York); with Michael Davidson on Therapeutic Lipidology (Humana, Philadelphia); with Domenic Sica on Current Controversies in Dyslipidemia Management (Atlas Publishing, Oxford); with Kevin Maki on Practical Lipid Management (Wiley-Blackstone, London); with Christopher Cannon on Comprehensive Cardiovascular Care in the Primary Care Setting (Springer Humana, Philadelphia); and with Domenic Sica on Clinical Challenges in Hypertension volumes I and II (Clinical Publishing, Oxford, UK). He has lectured on many topics in cardiovascular medicine throughout the US.

H. Bryan Brewer, Jr., MD, FNLA*

H. Bryan Brewer, Jr., MD, FNLA*
Director, Washington Cardiovascular Associates
Senior Research Consultant
Lipoprotein and Atherosclerosis Research
MedStar Research Institute
Washington Hospital Center
Washington, DC

H. Bryan Brewer Jr., MD is Director, Washington Cardiovascular Associates, Senior Research Consultant, Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute, a division of MedStar Research Institute, in Washington, DC.

Prior to joining MedStar, Dr. Brewer was Chief of the Molecular Disease Branch at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) in Bethesda, Maryland, a position he held from 1976 to 2005.
Dr. Brewer is a prominent researcher who has published more than 490 original manuscripts and 75 reviews and book chapters on the subjects of genetic dyslipoproteinemias, lipoprotein metabolism, and atherosclerosis. He was a member of the Board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States, and has served on the editorial boards of several prestigious journals. He is curent on the editorial board of Clinical Lipidology. Dr. Brewer's research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinemias. More recently, he has pioneered the use of transgenic mice and rabbits as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis.
A recipient of the JD Lane Investigator Award from the US Public Health Service, Dr. Brewer also received the Heinrich Wieland Prize from the Federal Republic of Germany and the Public Health Service Commendation Award, Meritorious & Service, Distinguished Service Medals from the NIH, George Lyman Duff Memorial Award Lecture, and the Robert I. Levy Award.
Dr. Brewer received his medical degree from Stanford University School of Medicine in California. After completing his internship and residency in internal medicine at Massachusetts General Hospital in Boston, Dr Brewer joined the NHLBI.

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
Professor of Medicine
Mount Sinai School of Medicine
Cardiometabolic Disorders
Mount Sinai Heart
New York, NY

Robert S. Rosenson, MD, is Professor of Medicine at the Mount Sinai School of Medicine where he serves as Director of Cardiometabolic Disorders. Dr. Rosenson earned his medical degree from Tulane University in New Orleans, Louisiana.  He then served his residency in medicine at Brigham and Women's Hospital in Boston, Massachusetts. He later completed a fellowship in cardiology at the University of Chicago that was followed by an additional year of training as a Research Associate in lipoprotein metabolism
Dr. Rosenson has been involved in numerous grant-supported research investigations studying the effects of lipid-lowering therapy, hypoglycemic therapy, and antihypertensive agents in inflammation, thrombogenesis, and rheology. He has served as Principal Investigator on a number of NIH-funded research studies, pharmaceutical-sponsored drug trials, and multicenter studies. Recently, he served as Global Principal Investigator of the PLASMA I, PLASMA II and FRANCIS trials.  He has been an invited speaker at more than 200 national and international association meetings, grand rounds, and symposia. He has authored nearly a total of 600 journal articles, book chapters, abstracts, and electronic publications for Up To Date Medicine. 
1. Explain current research defining the mechanisms underlying cholesteryl ester transfer protein (CETP) inhibition and its impact on HDL metabolism;
2. Describe the mechanisms involved in the production, metabolism, and functionality of HDL including how they relate to atherogenesis;
3. Discuss recent evidence regarding the utility of HDL as a target for CVD risk modification including the clinical implications for patient management;
4. Compare the relative effectiveness of existing treatments and emergent approaches to raise HDL and reduce CVD risk.
5. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families